Shares of Prothena Co. plc (NASDAQ:PRTA – Get Free Report) have been assigned an average rating of “Buy” from the eight analysts that are presently covering the company, MarketBeat reports. Eight investment analysts have rated the stock with a buy recommendation. The average 1-year price target among analysts that have issued ratings on the stock […]
Strs Ohio trimmed its position in Prothena Co. plc (NASDAQ:PRTA – Free Report) by 46.9% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 6,900 shares of the biotechnology company’s stock after selling 6,100 shares during the period. Strs Ohio’s holdings in Prothena were worth $332,000 as […]
Penserra Capital Management LLC bought a new position in shares of Prothena Co. plc (NASDAQ:PRTA – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,104 shares of the biotechnology company’s stock, valued at approximately $211,000. Several other […]
E Fund Management Co. Ltd. decreased its position in shares of Prothena Co. plc (NASDAQ:PRTA – Free Report) by 20.2% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,427 shares of the biotechnology company’s stock after selling 1,622 shares during the period. E […]
Prothena Co. plc (NASDAQ:PRTA – Get Free Report) has been given an average recommendation of “Moderate Buy” by the eight brokerages that are covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average 12-month target price among brokers […]